R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential

The researchers used a combination of in vitro pharmacology, neuronal culture experiments, and mouse behavioural assays. Treatments were randomised and experimenters were blinded to treatment conditions. Statistical analyses were done in GraphPad Prism, planned comparisons were specified in advance, and sample sizes were based on literature, pilot work, or power analysis. Both sexes were included, but the study was not powered to detect sex differences, so male and female data were combined. No data were excluded. For cell-based work, embryonic day 18 rat cortical neurons were cultured to assess dendritic arborisation and spine formation after treatment with R-MDMA, R-MDDMA, and related compounds. Cultures were analysed at different stages of maturation, with Sholl analysis used for dendritic complexity and imaging used to quantify spine density. Ketanserin, a 5-HT2 receptor antagonist, was used to test whether 5-HT2 signalling mediated neuroplastic effects. In mice, the authors measured body temperature, novelty-induced locomotion, and head-twitch response after intraperitoneal dosing of R-MDMA or R-MDDMA at 12.5, 25, or 50 mg/kg. Fear extinction was tested using cued fear conditioning on one day, drug administration before extinction training on the next day, and extinction memory testing 24 h later. Antidepressant-like effects were assessed in the tail suspension test 24 h after drug administration, and prosocial effects were evaluated using both a three-chamber social interaction test and a social conditioned place preference paradigm. Some behavioural experiments also included ketanserin pretreatment to determine receptor dependence. Mechanistic studies included a serotonin efflux assay in HEK293T cells expressing SERT, biosensor-based assays for 5-HT2A and 5-HT2C receptor activity, BRET-based Gq activation assays for 5-HT2A, 5-HT2B, and 5-HT2C receptors, and broad radioligand binding studies across more than 30 central nervous system targets. The methods text also states that both in vitro and in vivo experiments were conducted under institutional animal care approval and that the compounds were synthesised in-house and analytically characterised.

In cortical neuron cultures, all tested MDMA and MDDMA enantiomers increased dendritic branching in a concentration-dependent manner, with effects appearing in the nanomolar range. At 10 μM, all compounds and ketamine significantly increased dendritic arborisation versus vehicle. R-MDDMA showed the largest effect size, although it differed significantly only from S-MDMA. In more mature cultures, both R-MDDMA and R-MDMA at 1 μM increased spine density to a similar degree as ketamine. These findings indicate that R-MDDMA is a potent psychoplastogen in this system. In vivo safety-related assays showed that neither R-MDMA nor R-MDDMA increased core body temperature at any dose over 2 h. The highest dose of each caused a brief fall in temperature at 30 min that resolved by 60 min. In novelty-induced locomotion, R-MDMA had mixed effects: it reduced locomotion at 12.5 mg/kg but increased locomotion at 50 mg/kg, and all tested doses produced an anxiety-like pattern with reduced centre time. By contrast, R-MDDMA did not significantly alter locomotion or thigmotaxis at 12.5 or 25 mg/kg, although 50 mg/kg reduced locomotion and increased thigmotaxis. Neither compound produced a head-twitch response at any dose tested. In the fear extinction paradigm, both doses of R-MDMA reduced freezing during extinction training, whereas R-MDDMA did not affect freezing during training. However, at the next-day extinction test, mice treated with either dose of R-MDMA and with 12.5 mg/kg R-MDDMA showed reduced freezing relative to vehicle, while 25 mg/kg R-MDDMA also reduced freezing but not significantly. Overall, the authors interpret this as evidence that R-MDDMA can produce a sustained reduction in fear memory responses when administered before extinction learning. In the tail suspension test, 25 mg/kg R-MDDMA and 25 mg/kg R-MDMA reduced immobility 24 h after dosing to a degree comparable to ketamine. The lower dose of R-MDDMA did not produce this antidepressant-like effect. The authors describe this as the first report of an antidepressant-like response for R-MDMA in rodents. Prosocial testing found clear differences between the compounds. R,S-MDMA robustly increased social interaction in the three-chamber assay, but neither 12.5 mg/kg nor 25 mg/kg R-MDDMA did so. In social conditioned place preference, R,S-MDMA produced robust social place preference and R-MDMA showed a modest, non-significant trend, whereas R-MDDMA did not produce a statistically significant social place preference at either dose. The authors therefore conclude that R-MDDMA has moderate to no prosocial effects. Mechanistically, R-MDDMA did not induce serotonin release from SERT-expressing cells, whereas R-MDMA did. In biosensor assays, both compounds reduced sensor signals after serotonin stimulation in a pattern consistent with partial agonism or antagonism, with comparable potencies. In BRET assays, R-MDDMA acted as a partial agonist at 5-HT2A receptors with lower efficacy than R,S-MDMA, and at 5-HT2C receptors it also showed partial agonist activity. Strikingly, R-MDDMA did not activate 5-HT2B receptors at any concentration, which the authors emphasise because 5-HT2B agonism is linked to cardiac valvulopathy risk. Binding studies showed that, beyond the 5-HT2 family, R-MDDMA had substantial affinity mainly for α1 adrenergic, H1, and σ receptors, and did not show high affinity for monoamine transporters. Finally, ketanserin blocked the ability of both R-MDMA and R-MDDMA to increase dendritic branching, spine formation, and antidepressant-like effects in the tail suspension test, supporting a 5-HT2-dependent mechanism for their neuroplastic and behavioural actions.

The authors interpret the findings as showing that a small structural modification of R-MDMA produced a compound, R-MDDMA, that kept several therapeutically relevant properties while losing key liabilities associated with MDMA-like drugs. They argue that R-MDDMA retains psychoplastogenic activity, can support fear extinction learning, and can produce sustained antidepressant-like effects, but does not directly activate 5-HT2B receptors, does not trigger serotonin efflux, and shows little evidence of stimulant-like or prosocial activity at therapeutically relevant doses. In their view, this makes R-MDDMA a safer analogue than R-MDMA and adds to the growing group of non-hallucinogenic psychoplastogens. The discussion places these findings in the context of earlier research showing that R-MDMA is less dopaminergic and less abuse-prone than racemic MDMA, while still retaining therapeutic effects. The authors also connect their data to work suggesting that 5-HT2 receptor activation, rather than serotonin release alone, is important for cortical plasticity and durable behavioural effects. They note that the lack of 5-HT2B activation is especially important given the known association between this receptor and cardiac valvulopathy risk. Several limitations and uncertainties are acknowledged indirectly through the presentation of the data. The authors note that high doses of R-MDMA and R-MDDMA produced behavioural effects such as reduced locomotion and thigmotaxis, so dose clearly matters. They also state that R-MDDMA may be partially demethylated in vivo, but argue that this cannot account for the very different behavioural profiles of the two compounds. The extracted text does not show a detailed limitations subsection beyond these points. The authors also caution, by implication, that their evidence is preclinical and based on rodent and cellular models. In terms of implications, the authors suggest that direct 5-HT2 receptor activation may be a useful strategy for developing safer MDMA-like therapeutics. They also point to R-MDDMA as part of a broader effort to identify compounds with sustained therapeutic potential but less abuse liability and less psychostimulant activity than MDMA.

R-MDDMA is presented as a structurally related analogue of MDMA that preserves 5-HT2-dependent psychoplastogenic, fear-extinction-promoting, and antidepressant-like effects while improving the safety profile by avoiding serotonin release and 5-HT2B activation. The authors conclude that this work supports direct 5-HT2 receptor activation as a mechanism for the compound’s beneficial actions and positions R-MDDMA as a promising non-hallucinogenic psychoplastogen for further study.